SCHEMBL2977632

SCHEMBL2977632

CNC(=O)COC(=O)NC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.56
EPHX2 P34913 2/20 0.46
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43
FAAH O00519 1/20 0.43
HPGD P15428 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
CYP2C9 P11712 1/20 0.42
HSD11B1 P28845 1/20 0.42
HDAC4 P56524 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2980638 0.84 EPHX1 (0.55) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL3936610 0.82 KMT2A (0.41) EPHX1EPHX2ALDH1A1L3MBTL1THRB
SCHEMBL18926997 0.82 EPHX1 (0.70) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL2016955 0.81 EPHX1 (0.68) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL593633 0.81 USP2 (0.47) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL19708436 0.79 EPHX1 (0.76) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL17936450 0.79 EPHX1 (0.62) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL21738867 0.79 EPHX1 (0.62) EPHX1EPHX2ALDH1A1L3MBTL1MAPT
SCHEMBL31312274 0.79 EPHX1 (0.48) EPHX1ALDH1A1L3MBTL1MAPTNPC1
SCHEMBL13963459 0.79 EPHX1 (0.55) EPHX1EPHX2ALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
US-7781590-B2 Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 EPHX1 83/4885EPHX2 65/4885ALDH1A1 974/4885
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 EPHX1 121/4885EPHX2 115/4885ALDH1A1 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.